Tests chemoradiotherapy versus radiotherapy after surgery for early cervical cancer
Compares chemoradiotherapy with radiotherapy alone in adults with early cervical cancer after surgery.
Plain-language title generated from the registry record
Registry title: Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05277688, who can take part
Where in China
- Ruijin Hospital, Shanghai jiaotong univestigy school of medicineShanghai, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT05277688
- Record updated
- 18 August 2026
- Original description
To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.Read full original descriptionShow less
Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients With Selected Intermediate-risk Factors: a Randomized Controlled Phase III Trials (ACCEPT Trial)
To evaluate if adjuvant concurrent chemoradiotherapy is associated with a recurrence-free survival benefit in comparison with radiotherapy alone in selected intermediate risk cervical cancer after radical surgery.
Inclusion: • 18 Years to 80 Years; Histologically proven cervical cancer, FIGO stage Ia2-IIb,and no previous chemotherapy and radiotherapy; Accepted radical hysterectomy 3-4 weeks before; Karnofsky score >70; Postoperative pathology with one of the three risk factors criterials: (1) lympho-vascular space invasion(LVSI+) and deep 1/3 stromal invasion; (2 ) LVSI(+) and middle 1/3 stromal invasion, and tumor size≥4cm (3)Non-squamous cell carcinoma; Examination results showed no radiation or chemotherapy contraindication; Willing to accept treatment; Ability to comply with trial requirements.
Exclusion: • Postoperative residual; Postoperative recurrence or metastasis; Pelvic lymph node metastasis; parametrial invasion; positive surgical margin; Without lymph node dissection; Postoperative pathology showed aortic lymph node metastasis; Examination results showed radiotherapy contraindications; No indications for radiotherapy.